このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

多系統萎縮症の治療におけるTAK-341の研究

2026年8月31日 更新者:Takeda

多系統萎縮症の被験者における静脈内TAK-341の有効性、安全性、忍容性、薬物動態、および薬力学を評価するための無作為化、二重盲検、プラセボ対照、第2相試験

The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS).

The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo, after each infusion some blood samplings will be taken and other assessments completed.

This trial will be conducted in North America, Europe and Asia.

調査の概要

状態

完了

詳細な説明

The drug being tested in this study is called TAK-341. The study will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of intravenous (IV) TAK-341 in participants with multiple system atrophy (MSA).

The study will enroll approximately 158 participants. The study comprises a screening period of up to 42 days (6 weeks), a 52-week double-blind treatment period, and a follow-up safety visit. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant, care provider and investigator during the study:

  • TAK-341
  • Placebo

The change from baseline in UMSARS will be measured at Week 52 post-dose.

This multi-center trial will be conducted worldwide. The duration of treatment in this study will be 52 weeks. Participants will make a follow-up visit to the site after approximately 90 days after the last dose of study treatment.

研究の種類

介入

入学 (実際)

158

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Michigan
      • Farmington Hills、Michigan、アメリカ、48025
        • Quest Research Institute - Alcanza - HyperCore
    • Minnesota
      • Rochester、Minnesota、アメリカ、55905-0001
        • Mayo Clinic
    • New York
      • New York、New York、アメリカ、10016-6402
        • NYU Langone Health
    • North Carolina
      • Durham、North Carolina、アメリカ、27705-4410
        • Duke University School of Medicine
    • Ohio
      • Cleveland、Ohio、アメリカ、44195
        • The Cleveland Clinic Foundation
    • Texas
      • Dallas、Texas、アメリカ、75390-7208
        • University of Texas Southwestern Medical Center
    • Washington
      • Spokane、Washington、アメリカ、99202-1342
        • Inland Northwest Research
    • Hampshire
      • Southampton、Hampshire、イギリス、SO16 6YD
        • Southampton General Hospital
      • Salerno、イタリア、84131
        • Azienda Ospedaliera Universitaria OO.RR. San Giovanni di Dio Ruggi dAragona
    • Lazio
      • Rome、Lazio、イタリア、00163
        • IRCCS San Raffaele Roma
    • Lombardy
      • Milan、Lombardy、イタリア、20133
        • Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta
      • Milan、Lombardy、イタリア、20122
        • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
      • Rozzano、Lombardy、イタリア、20089
        • Istituto Clinico Humanitas
    • Veneto
      • Padova、Veneto、イタリア、35126
        • Azienda Ospedale Universita Padova
    • Styria
      • Graz、Styria、オーストリア、8036
        • Medizinische Universitat Graz
      • Barcelona、スペイン、08035
        • Hospital Universitario Vall d'Hebron
      • Barcelona、スペイン、08041
        • Hospital de La Santa Creu i Sant Pau
      • Madrid、スペイン、28034
        • Hospital Universitario Ramon y Cajal
      • Madrid、スペイン、28006
        • Hospital Universitario de La Princesa
      • Valencia、スペイン、46026
        • Hospital Universitari i Politecnic La Fe de Valencia
    • Vizcaya
      • Barakaldo、Vizcaya、スペイン、48903
        • Hospital Universitario Cruces
      • Aarhus N、デンマーク、8200
        • Aarhus Universitetshospital
    • Capital
      • København NV、Capital、デンマーク、2400
        • Bispebjerg Hospital
      • Berlin、ドイツ、10117
        • Charite - Universitatsmedizin Berlin
    • Bavaria
      • München、Bavaria、ドイツ、81377
        • Klinikum Groshadern, LMU
    • Hesse
      • Kassel、Hesse、ドイツ、34128
        • Paracelsus-Elena-Klinik Kassel
    • Lower Saxony
      • Hanover、Lower Saxony、ドイツ、30625
        • Medizinische Hochschule Hannover
    • North Rhine-Westphalia
      • Bochum、North Rhine-Westphalia、ドイツ、44791
        • Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB) - St. Josef-Hospital
      • Bonn、North Rhine-Westphalia、ドイツ、53127
        • Deutsches Zentrum fur Neurodegenerative Erkrankung
      • Münster、North Rhine-Westphalia、ドイツ、48149
        • Universitatsklinikum Munster
    • Saxony
      • Dresden、Saxony、ドイツ、01307
        • Universitatsklinikum Carl Gustav Carus an der TU Dresden
      • Leipzig、Saxony、ドイツ、04103
        • Universitatsklinikum Leipzig
    • Bouches-du-Rhone
      • Marseille、Bouches-du-Rhone、フランス、13385
        • Hopitaux de La Timone
    • Lisbon District
      • Loures、Lisbon District、ポルトガル、2674-514
        • Campus Neurologico Senior
    • Porto District
      • Senhora da Hora、Porto District、ポルトガル、4464-513
        • Hospital Pedro Hispano
    • Chiba
      • Chuo-ku、Chiba、日本、260-8677
        • Chiba University Hospital
    • Hokkaido
      • Sapporo、Hokkaido、日本、060-8638
        • Hokkaido University Hospital
    • Kyoto
      • Kyoto、Kyoto、日本、606-8507
        • Kyoto University Hospital
    • Tokyo
      • Bunkyo-Ku、Tokyo、日本、113-0033
        • The University of Tokyo Hospital
      • Bunkyo-Ku、Tokyo、日本、113-8519
        • Medical Hospital of Tokyo Medical and Dental University
      • Kodaira-Shi、Tokyo、日本、187-8551
        • National Center of Neurology and Psychiatry

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

40年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion criteria:

Diagnostic:

  1. The participant has a diagnosis of possible or probable MSA using the modified Gilman et al, 2008 diagnostic criteria.
  2. The participant's onset of first MSA symptoms occurred ≤4 years before screening, as assessed by the investigator.
  3. Evidence of MSA specific symptoms and deficits as measured by the UMSARS scale.

Exclusion criteria:

Medical History:

1. The participant has any contraindication to study procedures.

Diagnostic Assessments:

  1. Presence of confounding diagnosis and/or conditions that could affect participant's safety during the study per investigator judgement.
  2. The participant's participation in a previous study of a disease-modifying therapy (with proven receipt of active treatment) will compromise the interpretability of the data from the present study, per consultation with medical monitor or designee.

Other:

1. The participant has participated in another study investigating active or passive immunization against α-synuclein (αSYN) for progressive disease (PD) or MSA, or has had immunoglobulin G therapy, within 6 months before screening.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:Placebo

Participants received TAK-341 matching placebo intravenous (IV) infusions, once every 4 weeks (Q4W) for 52 weeks.

TAK-341-matching placebo IV infusion

実験的:TAK-341

Participants received TAK-341, IV Q4W for 52 weeks. An early set of participants initially received 2400 milligrams (mg) to determine pharmacokinetic (PK) parameters. Following the early participants, a dose of 2000 mg was given until the data from the PK participants became available. All participants then received 2400 mg until the end of treatment at 52 weeks.

TAK-341 IV infusion

他の名前:
  • MEDI1341

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52
時間枠:Baseline, Week 52

UMSARS Part I (historical review) is a 12-item scale that was adapted from the Unified Parkinson's Disease Rating Scale (UPDRS) and is used to assess activities related to motor disability and autonomic dysfunction. In this study, the UMSARS was modified to exclude the sexual function item. Thus, total 11 items were assessed. Each item was initially scored on a scale from 0 (normal) to 4 (severe); ratings of normal (0) and mild (1) were then combined and recorded as 0, making minimum score 0 and maximum score 3. The investigator rated the average functional situation for the past 2 weeks according to findings from the participant and caregiver interview and indicated the score that best fit with the participant's status. The total score is a sum of scores from all domains and range from 0 to 33. Higher scores indicate worse impairment.

Baseline, Week 52

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants With Anti-Drug Antibodies
時間枠:Up to Week 61
Up to Week 61
Change From Baseline in 11-item UMSARS at Week 52
時間枠:Baseline, Week 52

The 11- item UMSARS includes 11 items from Part I and II to assess both motor and autonomic disability. UMSARS Part I (historical review) is used to assess activities related to motor disability and autonomic dysfunction. UMSARS Part II (motor examination) is used to measure the functional impairment and specific parkinsonian or cerebellar features. Each item was scored on a scale from 0 (normal) to 4 (severe); total score ranges from 0 to 44, higher scores indicated worse impairment.

Baseline, Week 52
Change From Baseline in the UMSARS Total Score (UMSARS Part I + Part II) at Week 52
時間枠:Baseline, Week 52

UMSARS total scale consists of all items from UMSARS Parts I and II. UMSARS Part I (historical review): 12-item scale used to assess activities related to motor disability and autonomic dysfunction. Each item is scored from 0 (normal) to 4 (severe). UMSARS Part II (motor examination): 14-item scale used to measure the functional impairment (for example speech, rapid alternating movements of the hands, finger taps, leg agility) of selected complex movements, and specific parkinsonian (tremor at rest) or cerebellar (ocular motor dysfunction, heel-shin test) features. The worst affected limb was assessed, and each item was scored from 0 (normal) to 4 (severe). UMSARS Part I and Part II total score is the sum of UMSARS Part I and Part II and ranges from 0 to 104. A higher score indicates worse impairment.

Baseline, Week 52
Change From Baseline in UMSARS Part I 11-Item Score at Week 52
時間枠:Baseline, Week 52

UMSARS Part I (historical review) is a 12-item scale that was adapted from the UPDRS. In this study, the UMSARS was modified to exclude the sexual function item. The UMSARS is used to assess activities related to motor disability and autonomic dysfunction. Each item was scored on a scale from 0 (normal) to 4 (severe). UMSARS Part I 11-item total score is the total score of UMSARS Part I, excluding the sexual function item, and without collapse of ratings of scale items. The UMSARS Part I 11-item total score ranges from 0 to 44, and higher scores indicate worse impairment.

Baseline, Week 52
Change From Baseline in UMSARS Part II at Week 52
時間枠:Baseline, Week 52

UMSARS Part II (motor examination): 14-item scale used to measure the functional impairment (e.g., speech, rapid alternating movements of the hands, finger taps, leg agility) of selected complex movements, and specific parkinsonian (tremor at rest) or cerebellar (ocular motor dysfunction, heel-shin test) features. the worst affected limb was assessed, and each item was scored from 0 (normal) to 4 (severe). The UMSARS Part II total score ranges from 0 to 56, and higher scores indicate worse impairment.

Baseline, Week 52
Change From Baseline on Clinical Global Impression-Severity (CGI-S) Score
時間枠:Baseline, Week 24 and Week 52

The CGI-S is used to assess the clinician's impression of the participant's clinical condition. The clinician rates the current severity of the participant's illness on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (most extremely ill). The rating was based on observed and reported symptoms, behaviour, and function and reflected the severity level at the time of the assessment. A higher score indicates worse impairment.

Baseline, Week 24 and Week 52
Change From Baseline in Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA-AUT) Total Score
時間枠:Baseline, Week 24 and Week 52

The SCOPA-AUT is a participant-reported outcome that assesses autonomic function. Autonomic function is a critical symptom domain for MSA. The scale was completed by participants and consisted of 25 items assessing the following domains: gastrointestinal (7 items), urinary (6 items), cardiovascular (3 items), thermoregulatory (4 items), pupillomotor (1 item), and sexual (2 items for men and 2 items for women). The score for each item ranged from 0 (never experiencing the symptom) to 3 (often experiencing the symptom). The total composite score including all domains was reported. The score range was 0 (no symptoms) to 69 (highest burden of symptoms). A higher score indicates worse impairment.

Baseline, Week 24 and Week 52
Overall Survival (OS) at Week 52
時間枠:At Week 52

OS was estimated with Kaplan-Meier survival estimates, along with 95% confidence interval. A cox proportional hazards model was fitted to model the survival probability with treatment as the predictor. The participants with missing value were censored. The probabilities of survival at Week 52 for participants were estimated and reported.

At Week 52
Change From Baseline in Cerebrospinal Fluid (CSF) Free Alpha-Synuclein (αSYN)
時間枠:Baseline, Week 52

α-Synucleinopathies are diseases characterized by abnormal accumulation of aggregated αSYN. In participants with MSA, αSYN is seen to accumulate primarily in oligodendrocytes, forming glial cytoplasmic inclusions. A negative change from Baseline indicates an improvement.

Baseline, Week 52
Maximum Observed Steady State Serum Concentration (Cmax) for TAK-341
時間枠:On Day 57- immediately before end of infusion (EOI) (60 minutes), 6 hours and 24 hours.

Cmax is the maximum observed serum concentration for TAK-341.

On Day 57- immediately before end of infusion (EOI) (60 minutes), 6 hours and 24 hours.
Time to Maximum Steady State Concentration (Tmax) for TAK-341
時間枠:On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.

Tmax is the time of first occurrence of maximum observed concentration for TAK-341.

On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.
Area Under the Serum Concentration Time Curve (AUCτ) at Steady State for TAK-341
時間枠:On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.

AUCτ is the area under the serum concentration-time curve during a dosing interval.

On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.
CSF Concentration of TAK-341
時間枠:On Day 1, Day 85 and Day 365

Lumbar puncture was performed for CSF on Day 1, Day 85 and Day 365, predose.

On Day 1, Day 85 and Day 365
Number of Participants With at Least One Adverse Event (AE)
時間枠:Up to Week 61

An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event that occurs after administration of the first dose of study treatment and up through 90 days after the last dose of study treatment.

Up to Week 61

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • スタディディレクター:Medical Director、Takeda (Note: This product was divested to Alexion/AstraZeneca in 2026)

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年11月16日

一次修了 (実際)

2025年7月28日

研究の完了 (実際)

2025年7月28日

試験登録日

最初に提出

2022年9月1日

QC基準を満たした最初の提出物

2022年9月1日

最初の投稿 (実際)

2022年9月2日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月24日

QC基準を満たした最後の更新が送信されました

2026年8月31日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • TAK-341-2001
  • 2022-000336-28 (EudraCT番号)
  • jRCT2011220029 (レジストリ識別子:jRCT)
  • 2023-509876-40-00 (Ctis)
  • 2023 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する